ReviewCurrent treatment options in oncology2019
Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.
Review in Current treatment options in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Hotspots and future trends of dermatofibrosarcoma protuberans.Frontiers in oncology · 2024Pooled it
- Angiogenic and Stromal Remodeling Associated With Aggressive Fibrosarcomatous Dermatofibrosarcoma Protuberans.Cancer science · 2026Article
- Is Neoadjuvancy with Imatinib Useful Before Mohs Surgery in Locally Advanced Dermatofibrosarcoma Protuberans? Experience of a Dermato-Oncology Referral Center.International journal of molecular sciences · 2026Article
- Ultrasonic manifestation of dermatofibrosarcoma protuberans and differential diagnosis from superficial venous malformation: A retrospective study.The Journal of international medical research · 2026Article
- Reconstructive Surgery in the Elderly: A Case Report on Maintaining the Quality of Life in a Patient with Vulvar Dermatofibrosarcoma Protuberans.Diseases (Basel, Switzerland) · 2024Article
- The Role of Postoperative Radiotherapy in the Management of Dermatofibrosarcoma Protuberans: A Multidisciplinary Systematic Review.Journal of clinical medicine · 2024Review
- Conventional and contrast-enhanced ultrasound in the differential diagnosis of recurrent dermatofibrosarcoma protuberans and postoperative scar.BMC cancer · 2024Article
- Scrotal Dermatofibrosarcoma Protuberans in a Patient with Schizophrenia: A Case Report and Review of the Literature.Cureus · 2024Article
- Dermatofibrosarcoma protuberans: Case series in a tropical setting and review of literature.Rare tumors · 2024Article
- Extensive analysis of 59 sarcoma-related fusion genes identified pazopanib as a potential inhibitor to COL1A1-PDGFB fusion gene.Cancer science · 2023Article
- Progressive insights into fibrosarcoma diagnosis and treatment: leveraging fusion genes for advancements.Frontiers in cell and developmental biology · 2023Review
- Malignant Superficial Mesenchymal Tumors in Children.Cancers · 2022Review
- A Novel Prognostic Nomogram and Risk Classification System for Predicting Cancer-Specific Survival of Postoperative Fibrosarcoma Patients: A Large Cohort Retrospective Study.Journal of oncology · 2022Article
- Comprehensive analysis of transcriptome characteristics and identification ofFrontiers in genetics · 2022Article
- Novel TNC-PDGFD fusion in fibrosarcomatous dermatofibrosarcoma protuberans: a case report.Diagnostic pathology · 2021Article
- The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans.Bosnian journal of basic medical sciences · 2021Article
- Dermatofibrosarcoma protuberance in a black African cohort-a clinicopathologic study.Ecancermedicalscience · 2020Article
- Dermatofibrosarcoma protuberans - the use of neoadjuvant imatinib for treatment of an uncommon breast malignancy: a case report.Journal of medical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementCutaneous sarcoma is a group of malignant mesenchymal tumors primarily involving the dermis, and it is characterized by extreme clinicopathological heterogeneity. Although its occurrence rate is rare, dermatofibrosarcoma protuberans (DFSP) is one of the most common types of dermal sarcoma. DFSP grows slowly and tends to relapse locally after inadequate resection. There are various histological variants of DFSP tumors and it often mimics benign lesions such as dermatofibroma and scar, which make accurate diagnosis difficult and delayed, and some cases progress to the stage where the tumor is unresectable. Recent advancements in cancer genetics and molecular biology methods have elucidated the COL1A1-PDGFB fusion gene, some novel fusion gene variants and pathways related to DFSP pathogenesis that have resulted in the evolution of cutaneous sarcoma diagnosis and treatment. For example, some clinical studies have confirmed the efficacy of imatinib methylate, an αPDGFR-targeted therapy for unresectable or metastatic DFSP. The present review summarizes recent updates in DFSP research, diagnostics, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.